Optimizing Patient Care in NSCLC: A Targeted Patient-Centered Approach

Optimizing Patient Care in NSCLC: A Targeted Patient-Centered Approach
1 AMA PRA Category 1 Credit(s)
Launch Date:
February 02, 2016
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, nurse practitioners, physician assistants, and registered nurses

Relevant Terms:

Non-small cell lung cancer (NSCLC)

Daniel Morgensztern, MD

Daniel Morgensztern, MD
Associate Professor of Medicine
Director, Thoracic Medical Oncology
Washington University School of Medicine
St. Louis, MO

Daniel Morgensztern, MD, is an associate professor at Washington University School of Medicine and the director of thoracic medical oncology. He graduated from FTE Souza Marques in Brazil followed by residency in internal medicine and fellowship in hematology-oncology at the University of Miami School of Medicine. Among his awards are the first place in the Doctor’s Dilemma Competition from the American College of Physicians in Florida (2000), Young Investigator Award from the American Society of Clinical Oncology (2003), American Society of Clinical Oncology Merit Award (2004), David S. Fischer Award for Outstanding Teaching and Mentoring Fellows in Medical Oncology at the Yale Cancer Center (2013), and Teacher of the Year award for the Hematology-Oncology Fellowship Program at Washington University (2015).

Jared Weiss, MD

Jared Weiss, MD
Assistant Professor of Medicine
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Jared Weiss, MD, is an assistant professor of medicine at the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina. He completed his BS in neuroscience at Brown University in Providence, Rhode Island; his Doctor of Medicine at Yale University School of Medicine in New Haven, Connecticut; his residency in internal medicine at Beth Israel Deaconess Medical Center in Boston; and his fellowship at the Hospital of the University of Pennsylvania in Philadelphia.
Dr. Weiss’s teaching within the university is integrated with his clinical practice and research efforts. He is an active clinical trialist; he is currently the lead principal investigator (PI) on seven investigator-initiated trials and site PI on numerous others. Previous research has resulted in dozens of papers and abstracts.
Dr. Weiss is active in the area of direct patient education. He has generated more than 50 videos and articles for the cancer information website CancerGrace.org and also serves on its board. Dr. Weiss is an active advocate for lung cancer patients and serves on the board of the Lung Cancer Initiative of North Carolina. He is also active in physician education, travelling nationally as a discussant at American Society of Clinical Oncology and American Thoracic Society as well as delivering numerous continuing medical education lectures.

H. Jack West, MD

H. Jack West, MD
Medical Director, Thoracic Oncology Program, Swedish Cancer Institute
Web Editor, JAMA Oncology
Founder and President, GRACE: Global Resource for Advancing Cancer Education
Seattle, WA

H. Jack West, MD received a master of philosophy in experimental biology from Cambridge University in England on a Fulbright Scholarship and a medical degree (magna cum laude) from Harvard Medical School in Boston, where he also conducted research as a Howard Hughes Medical Student Fellow. Dr. West’s postdoctoral training included an internship and residency in internal medicine at Brigham and Women’s Hospital in Boston and a fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/University of Washington in Seattle. He joined Swedish Cancer Institute in late 2002 and continues to work there as a medical oncologist and serve as medical director of the Thoracic Oncology Program.
Dr. West has published numerous articles in the peer-reviewed literature and has authored several book chapters. He also now serves as the web editor of JAMA Oncology and is on the editorial boards of Journal of Clinical Oncology, Journal of Medicine, Clinical Lung Cancer, and Journal of Thoracic Disease, in addition to serving as an author of multiple lung cancer-related sections of UpToDate and as a reviewer for more than a dozen professional journals. Dr. West leads a wide range of clinical trials and has been actively involved with the SWOG Lung Cancer Committee on multiple recent studies, on which he serves as study coordinator/principal investigator.
Finally, Dr. West founded and continues to run the nonprofit organization GRACE: Global Resource for Advancing Cancer Education, as a source of timely, free information for patients and caregivers dealing with cancer. GRACE currently receives more than 50,000 visits per month from over 100 countries around the world.
1. Utilize a comprehensive understanding of histopathologic and molecular underpinnings of non-small cell lung cancer (NSCLC) and efficacy and safety data for agents used to treat NSCLC to select the most appropriate personalized therapies
2. Implement the most effective treatment strategies for patients with NSCLC using current evidence-based guidelines for sequencing, combination chemotherapy, and targeted therapy
3. Engage patients with NSCLC in their healthcare by implementing effective shared decision-making strategies

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Daniel Morgensztern, MD, has affiliations with Celgene, Genentech, and Heat Biologics (Consulting); and Boehringer Ingelheim and Genentech (Speaker).
  • Jared Weiss, MD, has affiliations with AstraZeneca, Biodesix, Clovis Oncology, Eli Lilly, EMD Serono, and OncoPlex (Consulting); and AstraZeneca, Celgene, Merck, Novartis, and Pfizer (Research).
  • H. Jack West, MD, has affiliations with ARIAD, AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Guardant Health, and Novartis (Consulting); and Boehringer Ingelheim (Non-CME/CE Services).
  • Sherri Lanza, MD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 1.0 hour
Medium: Internet

There is no fee for this educational activity.

This activity is supported by independent educational grants from Genentech and Lilly.

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above